[Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy].

about

[Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy].

Item

http://www.wikidata.org/entity/Q52836172

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

[Primary prophylaxis for venou ...... ients receiving chemotherapy].

@en

[Primary prophylaxis for venou ...... ients receiving chemotherapy].

@nl

type

Item

label

[Primary prophylaxis for venou ...... ients receiving chemotherapy].

@en

[Primary prophylaxis for venou ...... ients receiving chemotherapy].

@nl

prefLabel

[Primary prophylaxis for venou ...... ients receiving chemotherapy].

@en

[Primary prophylaxis for venou ...... ients receiving chemotherapy].

@nl

P1476

[Primary prophylaxis for venou ...... ients receiving chemotherapy].

@en

P2093

B Krabbe

http://www.w3.org/2001/XMLSchema#string

L-M Krabbe

http://www.w3.org/2001/XMLSchema#string

P2860

Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.

Development and validation of a predictive model for chemotherapy-associated thrombosis.

Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.

Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.

P304

1323-1326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00120-017-0489-Y

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28819678

http://www.w3.org/2001/XMLSchema#string